1 asset in Sinonasal Undifferentiated Carcinoma
Therapeutic assets addressing Sinonasal Undifferentiated Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
Tarlatamab Sinonasal Undifferentiated Carcinoma | University of Arizona | P1/2 | CCC (48) |